Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

被引:406
作者
Jamal, Sophie A. [1 ,2 ]
Vandermeer, Ben [6 ]
Raggi, Paolo [7 ]
Mendelssohn, David C. [5 ,10 ]
Chatterley, Trish [8 ]
Dorgan, Marlene [8 ]
Lok, Charmaine E. [3 ]
Fitchett, David [4 ]
Tsuyuki, Ross T. [9 ]
机构
[1] Univ Toronto, Womens Coll Hosp, Div Endocrinol & Metab, Toronto, ON, Canada
[2] Univ Toronto, St Michaels Hosp, Womens Coll Res Inst, Toronto, ON, Canada
[3] Univ Toronto, St Michaels Hosp, Div Nephrol, Toronto, ON, Canada
[4] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Univ Alberta, Alberta Res Ctr Hlth Evidence, Dept Pediat, Edmonton, AB, Canada
[7] Univ Alberta, Walter C Mackenzie Hlth Sci Ctr, Mazankowski Alberta Heart Inst, Edmonton, AB, Canada
[8] Univ Alberta, Walter C Mackenzie Hlth Sci Ctr, John W Scott Hlth Sci Lib, Edmonton, AB, Canada
[9] Univ Alberta, Div Cardiol, Edmonton, AB, Canada
[10] Humber River Reg Hosp, Dept Nephrol, Toronto, ON, Canada
关键词
CORONARY-ARTERY CALCIFICATION; HEMODIALYSIS-PATIENTS; AORTIC CALCIFICATION; RENAL-DISEASE; SEVELAMER; CARBONATE; PROGRESSION; IMPACT; PHOSPHORUS; METABOLISM;
D O I
10.1016/S0140-6736(13)60897-1
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background Phosphate binders (calcium-based and calcium-free) are recommended to lower serum phosphate and prevent hyperphosphataemia in patients with chronic kidney disease, but their effects on mortality and cardiovascular outcomes are unknown. We aimed to update our meta-analysis on the effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease. Methods We did a systematic review of articles published in any language after Aug 1, 2008, up until Oct 22, 2012, by searching Medline, Embase, International Pharmaceutical Abstracts, Cochrane Central Register of Controlled Trials, and Cumulative Index to Nursing and Allied Health Literature. We included all randomised and non-randomised trials that compared outcomes between patients with chronic kidney disease taking calcium-based phosphate binders with those taking non-calcium-based binders. Eligible studies, determined by consensus with predefined criteria, were reviewed, and data were extracted onto a standard form. We combined data from randomised trials to assess the primary outcome of all-cause mortality using the DerSimonian and Laird random effects model. Findings Our search identified 847 reports, of which eight new studies (five randomised trials) met our inclusion criteria and were added to the ten (nine randomised trials) included in our previous meta-analysis. Analysis of the 11 randomised trials (4622 patients) that reported an outcome of mortality showed that patients assigned to non-calcium-based binders had a 22% reduction in all-cause mortality compared with those assigned to calcium-based phosphate binders (risk ratio 0.78, 95% CI 0.61-0.98). Interpretation Non-calcium-based phosphate binders are associated with a decreased risk of all-cause mortality compared with calcium-based phosphate binders in patients with chronic kidney disease. Further studies are needed to identify causes of mortality and to assess whether mortality differs by type of non-calcium-based phosphate binder.
引用
收藏
页码:1268 / 1277
页数:10
相关论文
共 33 条
[1]
[Anonymous], AM SCHOLAR
[2]
Phosphate Binder Impact on Bone Remodeling and Coronary Calcification - Results from the BRiC Study [J].
Barreto, Daniela Veit ;
Barreto, Fellype de Carvalho ;
de Carvalho, Aluizio Barbosa ;
Cuppari, Lilian ;
Draibe, Sergio Antonio ;
Dalboni, Maria Aparecida ;
Affonso Moyses, Rosa Maria ;
Neves, Katia Rodrigues ;
Jorgetti, Vanda ;
Miname, Marcio ;
Santos, Raul D. ;
Fernandes Canziani, Maria Eugenia .
NEPHRON CLINICAL PRACTICE, 2008, 110 (04) :C273-C283
[3]
Does blinding of readers affect the results of meta-analyses? [J].
Berlin, JA .
LANCET, 1997, 350 (9072) :185-186
[4]
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients [J].
Block, G. A. ;
Raggi, P. ;
Bellasi, A. ;
Kooienga, L. ;
Spiegel, D. M. .
KIDNEY INTERNATIONAL, 2007, 71 (05) :438-441
[5]
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[6]
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis [J].
Block, GA ;
Spiegel, DM ;
Ehrlich, J ;
Mehta, R ;
Lindbergh, J ;
Dreisbach, A ;
Raggi, P .
KIDNEY INTERNATIONAL, 2005, 68 (04) :1815-1824
[7]
Effects of Phosphate Binders in Moderate CKD [J].
Block, Geoffrey A. ;
Wheeler, David C. ;
Persky, Martha S. ;
Kestenbaum, Bryan ;
Ketteler, Markus ;
Spiegel, David M. ;
Allison, Matthew A. ;
Asplin, John ;
Smits, Gerard ;
Hoofnagle, Andrew N. ;
Kooienga, Laura ;
Thadhani, Ravi ;
Mannstadt, Michael ;
Wolf, Myles ;
Chertow, Glenn M. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (08) :1407-1415
[8]
Survival in end stage renal disease: calcium carbonate vs. sevelamer [J].
Borzecki, A. M. ;
Lee, A. ;
Wang, S. W. ;
Brenner, L. ;
Kazis, L. E. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (06) :617-624
[9]
Braun J, 2004, CLIN NEPHROL, V62, P104
[10]
The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients [J].
Chertow, GM ;
Raggi, P ;
McCarthy, JT ;
Schulman, G ;
Silberzweig, J ;
Kuhlik, A ;
Goodman, WG ;
Boulay, A ;
Burke, SK ;
Toto, RD .
AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (05) :307-314